-
Nov 14, 2024 | 
onclive.com | Roy S. Herbst
CommentaryVideoNovember 14, 2024Author(s):Fact checked by:,Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer. “[EGFR]-targeted drugs emerged, and we saw activity in patients with lung cancer. It wasn’t known for approximately 4 to 6 years later that there were mutations that caused that, but we had a breakthrough, and then we built on that.”Roy S.
-
Oct 28, 2024 | 
onclive.com | Roy S. Herbst
CommentaryVideoOctober 28, 2024Author(s):Roy S. Herbst, MD, PhD, discusses ongoing, planned, and future research for the management of unmutated non–small cell lung cancer. Roy S.
-
Oct 9, 2024 | 
nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more
AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
-
Aug 2, 2024 | 
onclive.com | Roy S. Herbst
CommentaryVideoAugust 2, 2024Author(s):Fact checked by:Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing. Roy S.
-
Jul 31, 2024 | 
cancernetwork.com | Joshua K. Sabari |Roy S. Herbst |Edward Kim |Jyoti D Patel |Divya Gupta |Laila Gharzai | +3 more
2 Commerce Drive Cranbury, NJ 08512
-
Jul 31, 2024 | 
cancernetwork.com | Joshua K. Sabari |Roy S. Herbst |Edward Kim |Jyoti D Patel |Divya Gupta |Laila Gharzai | +3 more
2 Commerce Drive Cranbury, NJ 08512
-
Jul 31, 2024 | 
cancernetwork.com | Joshua K. Sabari |Roy S. Herbst |Edward Kim |Jyoti D Patel |Divya Gupta |Laila Gharzai | +3 more
2 Commerce Drive Cranbury, NJ 08512
-
Jul 23, 2024 | 
onclive.com | Roy S. Herbst
CommentaryVideoJuly 23, 2024Author(s):Fact checked by:Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC. Roy S.
-
May 13, 2024 | 
newswise.com | Eric S. Winer |Michael Cecchini |Roy S. Herbst |Barbara Burtness
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
-
Apr 1, 2024 | 
newswise.com | Roy S. Herbst |Patricia LoRusso
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading ConferenceOne of the largest global gatherings of cancer experts begins Friday in San Diego, at the annual meeting of the American Association of Cancer Research (AACR). The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress.
